Evidence map›Paper›PMID 34806054›Full record

ArticleJTO clinical and research reports2021

Technical Feasibility and Safety of Repeated Computed Tomography-Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC.

Puja Shahrouki, Jay M Lee, Jonathan Barclay, Sarah N Khan, Scott Genshaft, Fereidoun Abtin, Steven M Dubinett, Aaron Lisberg, Sherven Sharma, Edward B Garon and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Puja ShahroukiDepartment of Radiological Sciences, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California.
Jay M LeeDivision of Thoracic Surgery, Department of Surgery, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California.
Jonathan BarclayDepartment of Radiological Sciences, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California.
Sarah N KhanDepartment of Radiological Sciences, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California.
Scott GenshaftDepartment of Radiological Sciences, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California.
Fereidoun AbtinDepartment of Radiological Sciences, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California.
Steven M DubinettDivision of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California.
Aaron LisbergDivision of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California.
Sherven SharmaDivision of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California.
Edward B GaronDivision of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California.
Robert SuhDepartment of Radiological Sciences, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California.
University of California, Los Angeles · US

Funding

A model for predicting response to PD-1 inhibitors in NSCLCR01CA208403 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GARON, EDWARD B · 2017 to 2021
$3.2M
NCI NIH HHS R01 CA208403
6 · The paper itself

Abstract

introductionTo assess the technical feasibility and safety of repeated percutaneous computed tomography (CT)-guided transthoracic biopsies and intratumoral injections of gene-modified dendritic cells in metastatic NSCLC.

methodsA total of 15 patients with 15 NSCLC lesions measuring greater than 1.0 cm underwent two cycles of intratumoral biopsies and CCL21 dendritic cell injections separated by 7 days. All needle placements and injections were done under CT guidance. Clinical and imaging follow-up was done approximately 4 weeks after the first procedure. Safety and feasibility were determined as: (1) safety and feasibility similar to that of single-needle biopsy, and (2) an absence of serious adverse events defined as grade greater than or equal to three according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.

resultsA total of 30 percutaneous, transthoracic intratumoral biopsies and injections into the lung cancer were performed, two cycles (at d 0 and 7) received by each patient (311 biopsies and 96 intratumoral injections). All percutaneous cases achieved technical success with respect to needle placement for both biopsy and injection of CCL21 dendritic cells. Only minor complications were observed (grade <3), including pneumothorax (n = 10, 33%) and small postbiopsy hemorrhage (n = 2, 7%). Pneumothorax was moderate (n = 1) or trace (n = 9), with resolution of the moderate pneumothorax after manual aspiration without chest tube placement. No patient required chest tube placement. No other complications or serious adverse effects related to the biopsy or dendritic cell injection were noted. All patients were in stable condition after up to 4 hours in the recovery unit and were discharged home on the same day. No procedure-related complications were observed on imaging or clinical follow-up at 4 weeks.

conclusionsRepeated percutaneous, transthoracic CT-guided biopsies and intratumoral gene-modified cell-based immunotherapy injections into lung cancers are technically feasible, safe, and reproducible. There were no procedure-related serious (defined as grade ≥3) adverse events.

Indexed as

Dendritic cellsGene therapyImmunotherapyNon–small cell lung cancer

Identifiers

PMID34806054
PMCPMC8581369
OpenAlexW3206657851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.